Drug and Health Product Submissions Under Review (SUR): Supplemental submissions under review
This list is current as of: 2026-07-31.
An Excel version of the updated SUR List is available from the Overview page.
| Medicinal Ingredient(s) | Therapeutic Area | Year, Month Submission was Accepted into Review | Company Name (available for submissions accepted into review on or after October 1, 2018) | Submission 'Class' (if applicable) (available for submissions accepted into review on or after October 1, 2018) |
|---|---|---|---|---|
Acalabrutinib maleate |
Antineoplastic agents |
2025-12 |
AstraZeneca Canada Inc |
Part of an 'aligned review' with a health technology assessment organization |
Adalimumab |
Immunosuppressants |
2024-09 |
JAMP Pharma Corporation |
Biosimilar |
Aflibercept |
Ophthalmologicals |
2025-12 |
Bayer Inc |
Part of an 'aligned review' with a health technology assessment organization |
Alirocumab |
Lipid modifying agents |
2024-12 |
Sanofi-Aventis Canada Inc |
Not applicable |
Atezolizumab |
Antineoplastic agents |
2026-06 |
Hoffmann-la Roche Limited |
Being reviewed under the Priority Review Policy |
Baricitinib |
Immunosuppressants |
2026-03 |
Eli Lilly Canada Inc |
Not applicable |
Belzutifan |
Antineoplastic agents |
2025-12 |
Merck Canada Inc |
Part of an 'aligned review' with a health technology assessment organization |
Belzutifan |
Antineoplastic agents |
2026-03 |
Merck Canada Inc |
Not applicable |
Benralizumab |
Drugs for obstructive airway diseases |
2025-10 |
AstraZeneca Canada Inc |
Not applicable |
Berotralstat hydrochloride |
Other hematological agents |
2026-03 |
Biocryst Pharmaceuticals Inc |
Part of an 'aligned review' with a health technology assessment organization |
Brexpiprazole |
Psycholeptics |
2026-03 |
Otsuka Pharmaceutical Co Ltd |
Not applicable |
Budesonide, formoterol fumarate dihydrate, glycopyrronium bromide |
Drugs for obstructive airway diseases |
2025-10 |
AstraZeneca Canada Inc |
Not applicable |
Coagulation factors II (human), IX (human), VII (human), X (human), proteins C, S |
Antihemorrhagics |
2025-10 |
Octapharma Pharmazeutika Produktionsges M B H |
Not applicable |
Corynebacterium diphtheriae CRM-197 protein, pneumococcal conjugate serotype 33F, pneumococcal polysaccharide serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, deOAc15B, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 35B |
Vaccines |
2025-11 |
Merck Canada Inc |
Not applicable |
Daratumumab |
Antineoplastic agents |
2025-12 |
Janssen Inc |
Not applicable |
Delgocitinib |
Other dermatological preparations |
2026-05 |
Leo Pharma Inc |
Part of an 'aligned review' with a health technology assessment organization |
Drospirenone, estetrol monohydrate |
Sex hormones and modulators of the genital system |
2025-11 |
Searchlight Pharma Inc |
Not applicable |
Dupilumab |
Other dermatological preparations |
2025-11 |
Sanofi-Aventis Canada Inc |
Not applicable |
Dupilumab |
Other dermatological preparations |
2026-01 |
Sanofi-Aventis Canada Inc |
Not applicable |
Dupilumab |
Other dermatological preparations |
2026-02 |
Sanofi-Aventis Canada Inc |
Not applicable |
Durvalumab |
Antineoplastic agents |
2025-10 |
AstraZeneca Canada Inc |
Part of an 'aligned review' with a health technology assessment organization |
Efgartigimod alfa |
Immunosuppressants |
2026-04 |
Argenx BV |
Not applicable |
Elinzanetant |
Other gynecologicals |
2025-10 |
Bayer Inc |
Not applicable |
Enfortumab vedotin |
Antineoplastic agents |
2026-04 |
Pfizer Canada ULC |
Not applicable |
Epcoritamab |
Antineoplastic agents |
2026-03 |
Abbvie Corporation |
Being reviewed under the Priority Review Policy Part of an 'aligned review' with a health technology assessment organization |
Etonogestrel |
Sex hormones and modulators of the genital system |
2026-07 |
Organon Canada Inc. |
Not applicable |
Evolocumab |
Lipid modifying agents |
2026-06 |
Amgen Canada Inc |
Part of an 'aligned review' with a health technology assessment organization |
Fish oil, medium-chain triglycerides, olive oil, soybean oil |
Blood substitutes and perfusion solutions |
2025-11 |
Fresenius Kabi Canada Ltd |
Not applicable |
Guselkumab |
Immunosuppressants |
2025-01 |
Janssen Inc |
Not applicable |
Inclisiran sodium |
Lipid modifying agents |
2026-04 |
Novartis Pharmaceuticals Canada Inc |
Not applicable |
Iopromide |
Contrast media |
2025-12 |
Bayer Inc |
Being reviewed under the Submissions Relying on Third-Party Data Guidance |
Ipilimumab |
Antineoplastic agents |
2025-11 |
Bristol-Myers Squibb Canada |
Not applicable |
Larotrectinib sulfate |
Antineoplastic agents |
2025-11 |
Bayer Inc |
Not applicable |
Lisocabtagene maraleucel |
Antineoplastic agents |
2026-03 |
Bristol-Myers Squibb Canada |
Not applicable |
Lisocabtagene maraleucel |
Antineoplastic agents |
2026-04 |
Bristol-Myers Squibb Canada |
Not applicable |
Lurbinectedin |
Antineoplastic agents |
2025-08 |
Jazz Pharmaceuticals Ireland Limited |
Part of an 'aligned review' with a health technology assessment organization |
Lutetium (177Lu) vipivotide tetraxetan |
Therapeutic radiopharmaceuticals |
2026-05 |
Novartis Pharmaceuticals Canada |
Part of an 'aligned review' with a health technology assessment organization |
Maralixibat chloride |
Bile and liver therapy |
2026-07 |
Mirum Pharmaceuticals, Inc. |
Part of an 'aligned review' with a health technology assessment organization |
Mavacamten |
Cardiac therapy |
2026-07 |
Bristol-Myers Squibb Canada |
Being reviewed under the Priority Review Policy |
Melatonin |
Psycholeptics |
2026-07 |
Neurim Pharmaceuticals Ltd. |
Not applicable |
mRNA encoding SARS-CoV-2 spike protein NTD-RBD subdomains |
Vaccines |
2026-07 |
Moderna Biopharma Canada Corporation |
Not applicable |
Nipocalimab |
Immunosuppressants |
2026-07 |
Janssen Inc |
Not applicable |
Nivolumab |
Antineoplastic agents |
2025-11 |
Bristol-Myers Squibb Canada |
Not applicable |
Obinutuzumab |
Antineoplastic agents |
2026-04 |
Hoffmann-La Roche Limited |
Not applicable |
Ocrelizumab |
Immunosuppressants |
2026-01 |
Hoffmann-la Roche Limited |
Not applicable |
Olezarsen sodium |
Lipid modifying agents |
2026-07 |
Theratechnologies Inc |
Part of an 'aligned review' with a health technology assessment organization |
Peginterferon alfa-2a |
Immunostimulants |
2026-02 |
Pharmaand GmbH |
Not applicable |
Pembrolizumab |
Antineoplastic agents |
2026-03 |
Merck Canada Inc |
Not applicable |
Pembrolizumab |
Antineoplastic agents |
2026-04 |
Merck Canada Inc |
Not applicable |
Pembrolizumab |
Antineoplastic agents |
2026-05 |
Merck Canada Inc |
Not applicable |
Pirtobrutinib |
Antineoplastic agents |
2026-01 |
Eli Lilly Canada Inc |
Not applicable |
Pirtobrutinib |
Antineoplastic agents |
2026-03 |
Eli Lilly Canada Inc |
Not applicable |
Respiratory syncytial virus prefusion F protein (RSVPreF3) |
Vaccines |
2026-01 |
GlaxoSmithKline Inc |
Not applicable |
Risankizumab |
Immunosuppressants |
2025-12 |
Abbvie Corporation |
Part of an 'aligned review' with a health technology assessment organization |
Ritonavir |
Antivirals for systemic use |
2026-01 |
Abbvie Corporation |
Not applicable |
Roflumilast |
Antipsoriatics |
2025-10 |
Arcutis Canada, Inc. |
Not applicable |
Roflumilast |
Antipsoriatics |
2026-02 |
Arcutis Canada, Inc. |
Not applicable |
Sacituzumab govitecan |
Antineoplastic agents |
2026-01 |
Gilead Sciences Canada Inc |
Part of an 'aligned review' with a health technology assessment organization |
Sacituzumab govitecan |
Antineoplastic agents |
2026-01 |
Gilead Sciences Canada Inc |
Part of an 'aligned review' with a health technology assessment organization |
Semaglutide |
Drugs used in diabetes |
2026-01 |
Novo Nordisk Canada Inc |
Not applicable |
Setmelanotide acetate |
Antiobesity preparations, excluding diet products |
2026-03 |
Rhythm Pharmaceuticals, Inc |
Being reviewed under the Priority Review Policy |
Somapacitan |
Pituitary and hypothalamic hormones and analogues |
2026-06 |
Novo Nordisk Canada Inc |
Not applicable |
Talazoparib tosylate |
Antineoplastic agents |
2026-07 |
Pfizer Canada ULC |
Not applicable |
Talquetamab |
Antineoplastic agents |
2026-05 |
Janssen inc |
Not applicable |
Tapinarof |
Antipsoriatics |
2025-10 |
Organon Canada Inc. |
Not applicable |
Teclistamab |
Antineoplastic agents |
2026-04 |
Janssen Inc |
Not applicable |
Tirzepatide |
Drugs used in diabetes |
2025-12 |
Eli Lilly Canada Inc |
Not applicable |
Tirzepatide |
Drugs used in diabetes |
2026-02 |
Eli Lilly Canada Inc |
Not applicable |
Trastuzumab deruxtecan |
Antineoplastic agents |
2026-02 |
AstraZeneca Canada Inc |
Part of an 'aligned review' with a health technology assessment organization |
Trastuzumab deruxtecan |
Antineoplastic agents |
2026-03 |
AstraZeneca Canada Inc |
Being reviewed under the Priority Review Policy |
Trastuzumab deruxtecan |
Antineoplastic agents |
2026-03 |
AstraZeneca Canada Inc |
Part of an 'aligned review' with a health technology assessment organization |
Tucatinib |
Antineoplastic agents |
2026-06 |
Pfizer Canada ULC |
Not applicable |
Upadacitinib |
Immunosuppressants |
2026-02 |
Abbvie Corporation |
Part of an 'aligned review' with a health technology assessment organization |
Upadacitinib |
Immunosuppressants |
2026-06 |
Abbvie Corporation |
Not applicable |
Upadacitinib |
Immunosuppressants |
2026-07 |
Abbvie Corporation |
Not applicable |
Ustekinumab |
Immunosuppressants |
2026-02 |
Janssen Inc |
Not applicable |
Ustekinumab |
Immunosuppressants |
2026-05 |
Accord Healthcare Inc |
Biosimilar Part of an 'aligned review' with a health technology assessment organization |
Venetoclax |
Antineoplastic agents |
2026-06 |
Abbvie Corporation |
Not applicable |
Zanidatamab |
Antineoplastic agents |
2026-05 |
Jazz Pharmaceuticals Ireland Limited |
Not applicable |